Transdermal fentanyl for chronic low back pain.

Area of Science:

• Pain Management
• Pharmacology
• Clinical Research

Background:

• Chronic low back pain is a prevalent condition often inadequately managed by non-steroidal anti-inflammatory drugs.
• Opioid analgesics, including transdermal fentanyl, are increasingly considered for chronic non-cancer pain.
• Transdermal fentanyl has been available for chronic non-cancer pain in Japan since 2010.

Purpose of the Study:

• To evaluate the efficacy of transdermal fentanyl in managing chronic low back pain.
• To assess pain reduction and functional improvement in patients unresponsive to NSAIDs.
• To identify patient subgroups that benefit most from transdermal fentanyl therapy.

Main Methods:

• A cohort of 62 patients with chronic low back pain refractory to NSAIDs were enrolled.
• Patients received transdermal fentanyl, with dosages ranging from 12.5 to 50 μg/h.
• Visual analogue scale (VAS) and Oswestry Disability Index (ODI) scores were measured pre- and post-treatment, alongside adverse event monitoring.

Main Results:

• Transdermal fentanyl demonstrated significant improvements in both VAS and ODI scores.
• Efficacy was observed in 45 out of 62 patients (73%), with notable benefits in those with specific low back pain awaiting surgery.
• Adverse events, including constipation (29%), nausea (24%), and itching (24%), were reported in 40% of patients.

Conclusions:

• Transdermal fentanyl offers a significant therapeutic option for a majority of patients with chronic low back pain, especially those with specific conditions awaiting surgery.
• A subset of patients, particularly those with non-specific low back pain or a history of multiple back operations, did not experience pain relief.
• The study highlights the differential efficacy of transdermal fentanyl based on the underlying etiology of chronic low back pain.